Synapse

← Charles M. Perou

Papers by Charles M. Perou

Page 1 · newest first

  1. Transcriptomic Profiling of Mouse Mammary Tumors Enables Prognostic and Predictive Biomarker Discovery for Human Breast CancerCancer Research · 2026
  2. Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple negative breast cancer CALGB40603 (Alliance)Journal of Clinical Investigation · 2026
  3. Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast CancerMolecular Cancer Therapeutics · 2026
  4. Abstract 2009: Targeting metabolic vulnerabilities in basal-like breast cancer.Cancer Research · 2026
  5. Abstract 375: BRD8 chromatin regulator mediates anti-HER2 response in HR+/HER2+ breast cancer.Cancer Research · 2026
  6. Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast CancerCancer Research · 2026
  7. Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancersNature Communications · 2026
  8. Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer2025
  9. HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapyNature Communications · 2025
  10. Prognostic significance of CD8+ T cell Spatial Biomarkers in ER+ and ER− breast cancer: A retrospective cohort studyPLoS Medicine · 2025
  11. Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal AdenocarcinomaJCO Precision Oncology · 2025
  12. Integration of Digital Histology and Gene Expression to Predict Treatment-Specific Responses in Breast Cancer2025
  13. Integrative proteogenomics and forward genetics reveals a novel mitotic vulnerability in triple-negative breast cancer.2025
  14. Overexpression of TSG101 causes the development of adenosquamous mammary carcinomaBreast Cancer Research · 2025
  15. Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast CancerJAMA Network Open · 2025
  16. Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL TrialJCO Precision Oncology · 2025
  17. Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkersCell Reports Medicine · 2025
  18. Prognostic Significance of CD8 T-cell Spatial Biomarkers in ER+ and ER-Breast Cancer2025
  19. Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers2025
  20. B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancerJournal for ImmunoTherapy of Cancer · 2025
  21. 191MO Combination of talimogene laherparepvec (T-VEC) with atezolizumab (atezo) in patients (pts) with residual breast cancer (BC) after standard neoadjuvant chemotherapy (NAC): Survival results of the SOLTI-PROMETEO studyESMO Open · 2025
  22. HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabnpj Breast Cancer · 2025
  23. Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasetsnpj Breast Cancer · 2025
  24. Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancerJournal for ImmunoTherapy of Cancer · 2025
  25. Genomic Characteristics Related to Histology-Based Immune Features in Breast CancerModern Pathology · 2025
  26. Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profilingCell Genomics · 2025
  27. Understanding metastasis mixed-treatment responses through genomic analysesnpj Breast Cancer · 2025
  28. Genomic Analysis Reveals Racial and Age-Related Differences in the Somatic Landscape of Breast Cancer and the Association with Socioeconomic FactorsCancer Research · 2025
  29. Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapyCommunications Medicine · 2025
  30. Crafted experiments to evaluate feature selection methods for single-cell RNA-seq dataNAR Genomics and Bioinformatics · 2025
  31. Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer2024
  32. Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)Annals of Oncology · 2024
  33. Generative adversarial networks accurately reconstruct pan-cancer histology from pathologic, genomic, and radiographic latent featuresScience Advances · 2024
  34. TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapyAnnals of Oncology · 2024
  35. Quantitative proteomic mass spectrometry of protein kinases to determine dynamic heterogeneity of the human kinome2024
  36. Single‐cell transcriptional atlas of human breast cancers and model systemsClinical and Translational Medicine · 2024
  37. Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growthScience Advances · 2024
  38. Supplementary Data1 from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial2024
  39. Supplementary Data1 from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial2024
  40. Data from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial2024
  41. Supplementary Figure S2 from Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort2024
  42. Supplementary Figure S1 from Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort2024
  43. Supplementary Figure S1 from Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort2024
  44. Data from Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort2024
  45. Supplementary Figure S2 from Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort2024
  46. Stain SAN: simultaneous augmentation and normalization for histopathology imagesJournal of Medical Imaging · 2024
  47. Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502npj Breast Cancer · 2024
  48. Development and Characterization of Syngeneic Orthotopic Transplant Models of Obesity-Responsive Triple-Negative Breast Cancer in C57BL/6J MiceCancers · 2024
  49. Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapyBiomaterials · 2024
  50. Associations of immune checkpoint predictive biomarkers MHC-I and MHC-II with clinical and molecular features in a diverse breast cancer cohortClinical Cancer Research · 2024